PL3157548T3 - Terapia z zastosowaniem inhibitora czynnika xii w zaburzeniu neurotraumatycznym - Google Patents

Terapia z zastosowaniem inhibitora czynnika xii w zaburzeniu neurotraumatycznym

Info

Publication number
PL3157548T3
PL3157548T3 PL15741128T PL15741128T PL3157548T3 PL 3157548 T3 PL3157548 T3 PL 3157548T3 PL 15741128 T PL15741128 T PL 15741128T PL 15741128 T PL15741128 T PL 15741128T PL 3157548 T3 PL3157548 T3 PL 3157548T3
Authority
PL
Poland
Prior art keywords
therapy
factor xii
xii inhibitor
neurotraumatic disorder
neurotraumatic
Prior art date
Application number
PL15741128T
Other languages
English (en)
Inventor
Christoph Kleinschnitz
Marc Nolte
Anna-Leena SIRÉN
Christiane ALBERT-WEISSENBERGER
Sarah Hopp-Kraemer
Original Assignee
Csl Behring Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Csl Behring Gmbh filed Critical Csl Behring Gmbh
Publication of PL3157548T3 publication Critical patent/PL3157548T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81Protease inhibitors
    • C07K14/8107Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811Serine protease (E.C. 3.4.21) inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55Protease inhibitors
    • A61K38/57Protease inhibitors from animals; from humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55Protease inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76Albumins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81Protease inhibitors
    • C07K14/8107Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8135Kazal type inhibitors, e.g. pancreatic secretory inhibitor, ovomucoid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/31Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL15741128T 2014-06-18 2015-06-18 Terapia z zastosowaniem inhibitora czynnika xii w zaburzeniu neurotraumatycznym PL3157548T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14172910 2014-06-18
PCT/EP2015/063760 WO2015193457A1 (en) 2014-06-18 2015-06-18 Therapy using a factor xii inhibitor in a neurotraumatic disorder
EP15741128.1A EP3157548B1 (en) 2014-06-18 2015-06-18 Therapy using a factor xii inhibitor in a neurotraumatic disorder

Publications (1)

Publication Number Publication Date
PL3157548T3 true PL3157548T3 (pl) 2022-01-17

Family

ID=50972542

Family Applications (1)

Application Number Title Priority Date Filing Date
PL15741128T PL3157548T3 (pl) 2014-06-18 2015-06-18 Terapia z zastosowaniem inhibitora czynnika xii w zaburzeniu neurotraumatycznym

Country Status (12)

Country Link
US (2) US20170114119A1 (pl)
EP (1) EP3157548B1 (pl)
JP (1) JP7109160B2 (pl)
KR (1) KR102513050B1 (pl)
CN (1) CN106456778A (pl)
AU (1) AU2015276089B2 (pl)
BR (1) BR112016029624A2 (pl)
CA (1) CA2950988C (pl)
DK (1) DK3157548T3 (pl)
ES (1) ES2886859T3 (pl)
PL (1) PL3157548T3 (pl)
WO (1) WO2015193457A1 (pl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3157548B1 (en) 2014-06-18 2021-08-04 CSL Behring GmbH Therapy using a factor xii inhibitor in a neurotraumatic disorder
AU2016400019A1 (en) * 2016-03-30 2018-10-04 Sinntaxis AB Negative allosteric modulators of mGluR5 for use in the treatment of mature brain damages.
CN109071629A (zh) * 2016-04-06 2018-12-21 杰特有限公司 治疗动脉粥样硬化的方法
EP3723804A4 (en) 2017-12-15 2021-10-20 CSL Limited USE OF AN FXIIA INHIBITOR IN THE TREATMENT OF KIDNEY FIBROSIS AND / OR CHRONIC KIDNEY DISEASE
US12134657B2 (en) * 2018-11-28 2024-11-05 Oregon Health & Science University Therapeutic factor XII antibody
US20240228585A1 (en) * 2021-05-03 2024-07-11 President And Fellows Of Harvard College Fc-fusion protein therapeutic for the treatment of pancreatitis

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
US4963657A (en) 1988-06-09 1990-10-16 Temple University Of The Commonwealth System Of Higher Education Monoclonal antibodies to the light chain region of human factor XII and methods of preparing and using the same
JP2989002B2 (ja) 1988-12-22 1999-12-13 キリン―アムジエン・インコーポレーテツド 化学修飾顆粒球コロニー刺激因子
GB8901859D0 (en) 1989-01-27 1989-03-15 Shield Diagnostics Limited Diagnostic test
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
AU7793291A (en) 1990-05-10 1991-11-27 Cetus Corporation Inhibitors of factor xii activation and applications thereof
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
DK0575545T3 (da) 1991-03-15 2003-09-15 Amgen Inc Pegylering af polypeptider
JPH11501506A (ja) 1994-12-12 1999-02-09 ベス イスラエル デアコネス メディカル センター キメラ型サイトカインおよびその利用
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
EP1803730A1 (en) 2000-04-12 2007-07-04 Human Genome Sciences, Inc. Albumin fusion proteins
US20080108560A1 (en) 2002-03-05 2008-05-08 Eli Lilly And Company Heterologous G-Csf Fusion Proteins
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
EP3002012A1 (en) 2003-05-06 2016-04-06 Biogen Hemophilia Inc. Clotting factor-fc chimeric proteins to treat hemophilia
ES2371072T3 (es) 2003-06-12 2011-12-27 Eli Lilly And Company Proteínas de fusión análogas de glp-1.
CA2537273A1 (en) 2003-09-05 2005-03-17 Gtc Biotherapeutics, Inc. Method for the production of fusion proteins in transgenic mammal milk
WO2005063808A1 (en) 2003-12-31 2005-07-14 Merck Patent Gmbh Fc-ERYTHROPOIETIN FUSION PROTEIN WITH IMPROVED PHARMACOKINETICS
US8119137B2 (en) 2004-12-23 2012-02-21 Csl Behring Gmbh Prevention of thrombus formation and/or stabilization with inhibitors of factor XII or activated factor XII
WO2008098720A1 (en) 2007-02-12 2008-08-21 Csl Behring Gmbh Therapeutic application of kazal-type serine protease inhibitors
WO2011069090A1 (en) * 2009-12-04 2011-06-09 Alavita Pharmaceuticals, Inc. Inhibition of the activation of coagulation factor xii by ligands of phosphatidylserine
CA2821818A1 (en) 2010-12-17 2012-06-21 Anthrogenesis Corporation Treatment of spinal cord injury and traumatic brain injury using placental stem cells
EP2497489A1 (en) * 2011-03-09 2012-09-12 CSL Behring GmbH Factor XII inhibitors for the treatment of silent brain ischemia and ischemia of other organs
CN103415301A (zh) 2011-03-09 2013-11-27 德国杰特贝林生物制品有限公司 用于与包括与人造表面接触的医疗操作一起施用的fxii抑制剂
KR102042982B1 (ko) 2011-07-22 2019-11-11 체에스엘 베링 게엠베하 억제성 항-xii/xiia 인자 모노클로날 항체 및 이들의 사용
EP2548892A1 (en) * 2011-07-22 2013-01-23 CSL Behring GmbH Inhibitory anti-Factor XII/XIIa monoclonal Antibodies and their uses
US10471142B2 (en) 2011-09-24 2019-11-12 Csl Behring Gmbh Combination therapy using immunoglobulin and C1-Inhibitor
EP2623110A1 (en) 2012-01-31 2013-08-07 CSL Behring GmbH Factor XII inhibitors for the treatment of neurological inflammatory disorders
JP6636334B2 (ja) 2013-03-08 2020-01-29 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 遠隔虚血再灌流傷害の治療および予防
CA2916399C (en) 2013-06-28 2022-08-02 Marc Nolte Combination therapy using a factor xii inhibitor and a c1-inhibitor
US9587903B2 (en) 2014-02-24 2017-03-07 Brian E. Sullivan Pneumatic launcher system and method
EP3157548B1 (en) 2014-06-18 2021-08-04 CSL Behring GmbH Therapy using a factor xii inhibitor in a neurotraumatic disorder
CN109071629A (zh) 2016-04-06 2018-12-21 杰特有限公司 治疗动脉粥样硬化的方法

Also Published As

Publication number Publication date
US20170114119A1 (en) 2017-04-27
JP7109160B2 (ja) 2022-07-29
AU2015276089A1 (en) 2017-02-02
CA2950988A1 (en) 2015-12-23
DK3157548T3 (da) 2021-09-06
US12065481B2 (en) 2024-08-20
CN106456778A (zh) 2017-02-22
EP3157548B1 (en) 2021-08-04
US20200131248A1 (en) 2020-04-30
KR20170016503A (ko) 2017-02-13
EP3157548A1 (en) 2017-04-26
AU2015276089B2 (en) 2021-03-18
CA2950988C (en) 2024-02-06
WO2015193457A1 (en) 2015-12-23
JP2017524675A (ja) 2017-08-31
BR112016029624A2 (pt) 2017-10-24
KR102513050B1 (ko) 2023-03-29
ES2886859T3 (es) 2021-12-21

Similar Documents

Publication Publication Date Title
SI3256218T1 (sl) Inhibitor kdm1a in njegova uporaba v terapiji
SG10202005298RA (en) Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor
GB2531324B (en) A stylus
GB201517416D0 (en) Task-execution in a DBMS using stored procedures
SG11201607597SA (en) A stair
GB201405033D0 (en) Combination therapy
PL3230318T3 (pl) Kombinacje inhibitora immunologicznego punktu kontrolnego
GB201409535D0 (en) Arranging components in a two-dimensional area
PL3165360T3 (pl) Laminat
PL3230929T3 (pl) Udoskonalenia w zliczających urządzeniach
SG11201508893YA (en) Laminate
PL3157548T3 (pl) Terapia z zastosowaniem inhibitora czynnika xii w zaburzeniu neurotraumatycznym
GB2523128B (en) Improvements in or relating to a secondary drive unit
GB201322628D0 (en) A game apparatus
GB201416500D0 (en) A chair back
IL249240A0 (en) Combined treatment
GB2526425B (en) A face guard
PL3739138T3 (pl) Plac zabaw
TWI561187B (en) A furniture device
HK1232804A1 (en) Therapy using a factor xii inhibitor in a neurotraumatic disorder
GB201311986D0 (en) A training shoe
PH32014001219S1 (en) A chair
PH32014000923S1 (en) A chair
AU356454S (en) A chair
GB201402253D0 (en) A chair